The World EPA Congress in Amsterdam did not feel like a conference about isolated trends. It felt like a conference about structural transition.

Across sessions and conversations, one consistent narrative emerged: market access is being reshaped simultaneously by tightening policy frameworks and by the operational maturation of artificial intelligence. These are not parallel stories unfolding independently. They are interacting forces that together are redefining how evidence is generated, how value is assessed, and how global pricing strategies are constructed.

The underlying question throughout WEPA was not whether change is coming. It was whether organizations are structurally prepared to manage both forces at once.

1. A policy environment under structural redesign

Joint Clinical Assessment: Harmonization meets operational reality

The first year of Joint Clinical Assessment (JCA) implementation under the EU HTA Regulation represents a historic step toward harmonization of clinical evaluations across Europe. In principle, a single European-level clinical assessment promises efficiency, reduced duplication, and greater consistency in evaluating comparative effectiveness.

Yet the operational reality is more complex. Harmonization does not automatically mean simplification.

Early experience indicates that alignment between EU-level assessments and national reimbursement processes remains incomplete. Questions persist around how Member States will operationalize JCA outputs, how quickly EU HTAR assessors can deliver assessments, and whether national HTA bodies are fully prepared to transition to reliance on joint evaluations.

Methodological challenges are also emerging. PICO multiplicity, expanded evidence requirements, and the risk of unexpected analytical requests are increasing the burden on evidence generation teams, especially for products targeting rare diseases. While duplication of assessments may decrease, the sophistication and coordination required to navigate the system are increasing.

JCA is a milestone in European collaboration. But its success will depend on tighter synchronization between EU-level clinical conclusions and national pricing and reimbursement realities.

Real-world evidence: From complementary input to strategic pillar

Alongside JCA, the role of real-world evidence (RWE) is evolving rapidly. Regulators, payers, and clinicians increasingly seek insight into how therapies perform in routine clinical practice across diverse populations. The European Medicines Agency has clearly signaled its ambition to place patient voice and real-world data at the center of regulatory evaluation.

RWE is no longer supplementary. It is becoming central.

However, tension remains within the EU HTAR context. JCA assessments emphasize statistical precision and internal validity, while real-world evidence reflects the inherent heterogeneity of clinical practice. Methodological expectations between regulatory and HTA frameworks are not yet fully synchronized.

Europe now faces a strategic choice: either build robust, interoperable infrastructures for high-quality real-world data sharing across Member States, or risk creating friction between regulatory innovation and HTA conservatism. The credibility of future evidence strategies will depend on resolving this gap.

MFN pricing: Global interdependence redefines strategy

At the global level, Most-Favored-Nation (MFN) pricing dynamics are reshaping launch and market access strategies beyond the United States. Pricing has become an interconnected global system rather than a sequence of independent national decisions.

Launch sequencing is being reassessed as companies evaluate exposure to international reference pricing and MFN-linked rules. Markets are increasingly categorized by strategic risk, and cross-market interdependence is intensifying. Decisions taken in one jurisdiction reverberate across others.

Europe, despite its strong regulatory institutions, faces pressure due to fragmented access pathways, evolving JCA processes, and uncertainty in national budget negotiations. The traditional logic of “where to launch first” has become a far more complex strategic equation.

Taken together, JCA implementation, the rise of RWE, and MFN pricing pressures are increasing analytical complexity, accelerating timelines, and demanding greater coordination across functions and geographies. This rising structural pressure forms the backdrop to the second defining theme of WEPA.

2. AI moves from experimentation to operating model

From hype to governance

If policy discussions reflected systemic pressure, AI discussions reflected systemic adaptation.

The tone around artificial intelligence at WEPA 2026 was notably mature. The conversation quickly moved beyond questioning whether AI is hype. The focus shifted toward responsible operationalization, governance, and measurable value creation within regulated environments.

The key issue is no longer adoption. It is integration.

Organizations are developing governance frameworks, embedding AI into regulated workflows, and ensuring traceability and auditability of outputs. The emphasis is on scale and accountability rather than isolated experimentation.

AI as infrastructure in market access

Across sessions, AI was framed not as a productivity enhancement tool but as part of the operating model of modern market access organizations.

Companies are redesigning processes around AI-enabled capabilities. Evidence synthesis, systematic literature reviews, indirect treatment comparisons, dossier drafting, pricing simulations, and tender strategy development are increasingly supported by automated or semi-automated systems.

This represents a structural shift. AI is moving from peripheral pilot projects to enterprise-level infrastructure embedded within core functions.

In an environment where JCA increases analytical burden and MFN pricing demands multi-country scenario modeling, such capabilities are becoming operationally essential rather than optional.

From assistant to strategic copilot

One of the most forward-looking discussions centered on the evolution of AI from drafting assistant to strategic copilot.

The emergence of agentic AI and orchestration systems is enabling decision support in areas such as pricing negotiation, tender simulations, and contracting strategy optimization. Rather than merely accelerating document preparation, AI is beginning to inform strategic decision-making.

However, in highly regulated settings such as HTA and pricing negotiations, transparency and explainability remain non-negotiable. The credibility of AI-driven insights depends on robust governance and clear traceability.

The opportunity is substantial — speed, standardization, and efficiency. The responsibility is equally significant.

3. The convergence: Complexity requires capability

The most important insight from WEPA Amsterdam lies not in policy alone, nor in AI alone, but in their convergence.

Policy reforms are increasing complexity. JCA raises expectations for comparative evidence coordination across Europe. Real-world evidence demands stronger data ecosystems. MFN pricing intensifies global interdependence and strategic sensitivity.

At the same time, AI provides the analytical and operational capabilities necessary to manage this complexity. It enables faster synthesis of comparative data, structured analysis of heterogeneous real-world evidence, and dynamic cross-market pricing simulations.

In this sense, policy pressure and AI capability are two sides of the same transformation. The former raises the bar; the latter provides the tools to reach it.

The defining question for market access organizations is whether they can redesign their operating models quickly enough to integrate policy intelligence, evidence generation, pricing foresight, and AI-enabled execution into a coherent system.

WEPA 2026 signaled that the era of treating these dynamics as separate conversations is over. Market access is entering a phase where structural policy reform and technological capability must be managed together.

Those who integrate both dimensions — responsibly, transparently, and strategically — will shape the future of evidence-based access in Europe and beyond.

Share Via